ADAR1 Capital Management »

Miragen Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Miragen Therapeutics (VRDN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Miragen Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Miragen Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Miragen Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $45k 2.6k 17.51

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Miragen Therapeutics

BlackRock
BlackRock
Deep Track Capital
VR Adviser
Fairmount Funds Management
Vanguard Group
Paradigm Biocapital Advisors
Perceptive Advisors
State Street Corporation
Commodore Capital
Novo A/S
Tang Capital Management
Alliancebernstein
Maverick Capital
Driehaus Capital Management

View all funds holding Miragen Therapeutics